Efficiency of preventive use of bemethyl during long-term voyages
Controlled study in people · 1991
- What was studied
- 298 maritime operators aged 19–38: 148 Bemitil, 150 placebo controls; detailed laboratory and performance tests in a 20-person subset
- Main finding
- The voyage comparison reported 20% fewer complaints, 6.7% shorter simple-reaction latency, half as many complex-reaction errors and 13.7% greater static-effort endurance in Bemitil-treated sailors. The original also reports laboratory results, adverse reactions and 30-day post-treatment follow-up.
Related evidence maps: Military & occupational ↗
Reported findings and study design
The 298-person voyage comparison reported fewer complaints and better performance measures with Bemitil. Detailed immune and performance measurements were made in a 20-person subset. The paper also reports laboratory changes, adverse reactions and follow-up 30 days after treatment stopped.
298 maritime operators aged 19–38: Bemitil 148, placebo control 150. Detailed resistance and performance testing involved 20 people; their allocation is not stated clearly. Treatment began after one month at sea: 250–500 mg/day for 14 days. Examinations took place before, during and after prolonged voyages.
Population or model 298 maritime operators aged 19–38: 148 Bemitil, 150 placebo controls; detailed laboratory and performance tests in a 20-person subset
Dose, route and schedule
250–500 mg/day for 14 days, beginning after one month at sea. Placebo controls. Measurements before, during and after voyages, including 30 days after treatment stopped. Route not explicitly stated in the inspected Russian methods.
Protocol source ↗ · Original scan, printed page 37
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fatigue, poor mood, headache and insomnia complaints | 20% lower frequency | Authors’ reported change in treated sailors; absolute complaint counts are not given · After the course; precise assessment interval is not separately stated |
| Simple sensorimotor reaction | 6.7% shorter latency | Reported change in treated sailors |
| Complex sensorimotor reaction | Errors reduced twofold | Reported change in treated sailors; raw error totals not printed |
| Static-effort endurance | 13.7% increase | Reported change in treated sailors |
| Critical flicker fusion and two-minute step-test index | Both increased | No numerical amount given in the narrative |
| Phagocyte uptake capacity | 40.2% increase | Narrative report after the 14-day course; Table 1 gives 20.08 → 28.15 relative units |
| Phagocytosis intensity | 18% increase reported in narrative | The narrative separately says the degree of phagocytic reaction did not change; Table 1 reports a different measure. These endpoints should not be merged. |
| Phagocyte loss after 120 minutes | 24.4% → 14.9% | Reported reduction in relative cell loss · p<0.05 |
| Serum lysozyme and bactericidal activity | Maintained in treated sailors | Control values fell 11.7% and 6.1%, respectively |
| Skin bactericidal index | 18.9% increase | Narrative change after treatment; raw values in Table 1 |
| Skin microbial contamination | 41% reduction | p<0.01 |
| Overall morbidity | 18.3% treated; 81.7% control | The paper prints these percentages without raw case counts or a clear denominator. They must not be converted to individual illness risks or a relative-risk reduction. |
| Respiratory and class-I illnesses | 29% treated; 42% control | Share of first medical consultations, not the proportion of all sailors who became ill |
| Allergic reactions | 2% reported | Denominator and diagnostic criteria not separately tabulated |
| Reduced appetite | 2.7% reported | |
| Nausea | 0.7% reported | |
| Persistence after stopping treatment | Measurements repeated 30 days after withdrawal | Authors describe resistance and performance as maintained or improved; Tables 1–2 provide the laboratory values |
Table 1 · Nonspecific-defense measures
| Measure / unit | Group | Baseline | Day 14 of treatment | 30 days after withdrawal |
|---|---|---|---|---|
| Phagocyte uptake capacity / relative units | Control | 20.97 ± 1.75 | 19.67 ± 2.19 | 11.54 ± 1.19* |
| Phagocyte uptake capacity / relative units | Bemitil | 20.08 ± 0.87 | 28.15 ± 2.17** | 23.53 ± 2.28** |
| Degree of phagocytic reaction / relative units | Control | 0.66 ± 0.03 | 1.33 ± 0.08* | 1.44 ± 0.09* |
| Degree of phagocytic reaction / relative units | Bemitil | 0.84 ± 0.09 | 0.82 ± 0.04** | 0.60 ± 0.06** |
| Serum lysozyme activity / % | Control | 48.63 ± 1.78 | 42.96 ± 1.15* | 39.90 ± 0.97* |
| Serum lysozyme activity / % | Bemitil | 49.68 ± 1.76 | 49.11 ± 1.66** | 50.15 ± 1.62** |
| Serum bactericidal capacity / % | Control | 16.27 ± 0.45 | 15.30 ± 0.31 | 14.44 ± 0.30* |
| Serum bactericidal capacity / % | Bemitil | 16.81 ± 0.34 | 16.89 ± 0.39 | 17.80 ± 0.54** |
| Skin bactericidal index / % | Control | 70.91 ± 2.28 | 66.05 ± 1.08 | 62.39 ± 1.36* |
| Skin bactericidal index / % | Bemitil | 66.40 ± 2.59 | 79.0 ± 1.11*** | 82.40 ± 2.01*** |
Values reproduced as M ± m in the source. * versus baseline, p<0.025; ** versus control, p<0.01; *** versus control p<0.02 and baseline p<0.01. Measures are laboratory endpoints; the original does not specify the 20-person subset split.
Table 2 · Leukocyte cytochemical measures
| Measure / relative units | Group | Baseline | Day 14 of treatment | 30 days after withdrawal |
|---|---|---|---|---|
| Glycogen | Control | 1.62 ± 0.04 | 1.58 ± 0.03 | 1.51 ± 0.04 |
| Glycogen | Bemitil | 1.70 ± 0.05 | 1.86 ± 0.02* | 1.91 ± 0.03* |
| Lipids | Control | 1.68 ± 0.03 | 1.67 ± 0.03 | 1.64 ± 0.03 |
| Lipids | Bemitil | 1.72 ± 0.02 | 1.82 ± 0.02* | 1.83 ± 0.03* |
| Peroxidase | Control | 1.80 ± 0.06 | 1.78 ± 0.06 | 1.73 ± 0.05 |
| Peroxidase | Bemitil | 1.86 ± 0.05 | 1.93 ± 0.03** | 1.97 ± 0.03* |
Values reproduced as M ± m. * versus baseline, p<0.02; ** versus control, p<0.002.
Placebo comparison; randomization and blinding procedures are not described. Performance findings apply to this voyage setting. Morbidity denominators and the detailed-testing subgroup require clarification; no risk reduction has been calculated from the printed morbidity percentages.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Randomization and blinding procedures are not described. The 20-person testing subset is not broken down by treatment arm.
- The overall morbidity figures, 18.3% and 81.7%, lack underlying counts and an unambiguous denominator; they cannot be treated as individual illness risks.
- The narrative reports an 18% increase in phagocytosis intensity while a separate degree-of-reaction endpoint is unchanged; distinct measures must not be combined.
Source details
Recovered original journal scan, pages 37–39
Recovered original scan, printed pages 37–39: cohort, regimen, all narrative numerical findings and Tables 1–2 visually checked on 29 October 2026. Morbidity percentages lack clear denominators; no risk reduction was calculated.
All three pages and Tables 1–2 visually checked
Sources checked
Citation
V. S. Novikov, V. N. Bortnovskii, I. A. Shamarin. Efficiency of preventive use of bemethyl during long-term voyages Gig Sanit. (3):37–39